These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

227 related items for PubMed ID: 20981125

  • 1. Targeted therapies: Tyrosine-kinase inhibitors--new standard for NSCLC therapy.
    Saijo N.
    Nat Rev Clin Oncol; 2010 Nov; 7(11):618-9. PubMed ID: 20981125
    [No Abstract] [Full Text] [Related]

  • 2. NSCLC drug targets acquire new visibility.
    Friedrich MJ.
    J Natl Cancer Inst; 2011 Mar 02; 103(5):366-7. PubMed ID: 21357596
    [No Abstract] [Full Text] [Related]

  • 3. Time for molecularly targeted maintenance therapy for non-small-cell lung cancer?
    Stinchcombe TE, Ramalingam SS.
    Lancet Oncol; 2010 Jun 02; 11(6):500-1. PubMed ID: 20493770
    [No Abstract] [Full Text] [Related]

  • 4. Clinical development of gefitinib in non-small-cell lung cancer and the Iressa Survival Evaluation in Lung Cancer trial.
    Price N, Belani C.
    Clin Lung Cancer; 2005 Jan 02; 6(4):214-6. PubMed ID: 15694012
    [No Abstract] [Full Text] [Related]

  • 5. Mutations in the epidermal growth factor receptor tyrosine kinase may predict response to gefitinib in non-small-cell lung cancer.
    Clin Lung Cancer; 2004 May 02; 5(6):331-2. PubMed ID: 15217530
    [No Abstract] [Full Text] [Related]

  • 6. Clairvoyance or reliable prediction of the future?
    van Zandwijk N, van de Vijver MJ.
    Ann Oncol; 2007 Mar 02; 18(3):407-8. PubMed ID: 17322538
    [No Abstract] [Full Text] [Related]

  • 7. Gefitinib in non small cell lung cancer.
    Costanzo R, Piccirillo MC, Sandomenico C, Carillio G, Montanino A, Daniele G, Giordano P, Bryce J, De Feo G, Di Maio M, Rocco G, Normanno N, Perrone F, Morabito A.
    J Biomed Biotechnol; 2011 Mar 02; 2011():815269. PubMed ID: 21660144
    [Abstract] [Full Text] [Related]

  • 8. [Resistant mechanism and treatment strategy of tyrosine kinase inhibitors].
    Qiao J, Chen W.
    Zhongguo Fei Ai Za Zhi; 2011 Oct 02; 14(10):806-10. PubMed ID: 22008111
    [No Abstract] [Full Text] [Related]

  • 9. Differential responses to erlotinib in epidermal growth factor receptor (EGFR)-mutated lung cancers with acquired resistance to gefitinib carrying the L747S or T790M secondary mutations.
    Costa DB, Schumer ST, Tenen DG, Kobayashi S.
    J Clin Oncol; 2008 Mar 01; 26(7):1182-4; author reply 1184-6. PubMed ID: 18309959
    [No Abstract] [Full Text] [Related]

  • 10. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
    Greenhalgh J, Dwan K, Boland A, Bates V, Vecchio F, Dundar Y, Jain P, Green JA.
    Cochrane Database Syst Rev; 2016 May 25; (5):CD010383. PubMed ID: 27223332
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Role of tyrosine kinase inhibitors in lung cancer.
    Ansari J, Palmer DH, Rea DW, Hussain SA.
    Anticancer Agents Med Chem; 2009 Jun 25; 9(5):569-75. PubMed ID: 19519298
    [Abstract] [Full Text] [Related]

  • 16. EGFR pharmacogenomics: the story continues to mutate and evolve.
    Desai AA, Ratain MJ.
    Am J Pharmacogenomics; 2005 Jun 25; 5(2):137-9. PubMed ID: 15813677
    [No Abstract] [Full Text] [Related]

  • 17. Gefitinib for non-small cell lung cancer patients with liver cirrhosis.
    Kim YH, Mio T, Mishima M.
    Intern Med; 2009 Jun 25; 48(18):1677-9. PubMed ID: 19755773
    [Abstract] [Full Text] [Related]

  • 18. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR.
    Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I, Fujita Y, Okinaga S, Hirano H, Yoshimori K, Harada T, Ogura T, Ando M, Miyazawa H, Tanaka T, Saijo Y, Hagiwara K, Morita S, Nukiwa T, North-East Japan Study Group.
    N Engl J Med; 2010 Jun 24; 362(25):2380-8. PubMed ID: 20573926
    [Abstract] [Full Text] [Related]

  • 19. Third-generation EGFR-TKIs—a new hope for NSCLC.
    Akkermans R.
    Lancet Respir Med; 2014 Jul 24; 2(7):520. PubMed ID: 25140365
    [No Abstract] [Full Text] [Related]

  • 20. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.
    Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J, Haber DA.
    N Engl J Med; 2004 May 20; 350(21):2129-39. PubMed ID: 15118073
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.